Table 4.
Metabolic parameters at baseline (J0) and after 12 weeks (M3) of placebo or statin treatment.
| J0 | M3 | Change M3 − J0 | Difference in change (95% CI) | |
|---|---|---|---|---|
| Total cholesterol (g/L) | ||||
| Placebo (n = 26) | 2.25 ± 0.64 | 2.36 ± 1.24 | 0.11 ± 1.18 | −0.89 (−1.50; −0.27) |
| Statin (n = 25) | 2.45 ± 0.94$ | 1.68 ± 0.42§ | −0.78 ± 0.99£ | |
| LDL cholesterol (g/L) | ||||
| Placebo (n = 26) | 1.41 ± 0.45 | 1.34 ± 0.46 | −0.07 ± 0.38 | −0.65 (−0.96; −0.34) |
| Statin (n = 25) | 1.60 ± 0.66 | 0.88 ± 0.30 | −0.72 ± 0.67 | |
| HDL cholesterol (g/L) | ||||
| Placebo (n = 26) | 0.54 ± 0.23 | 0.74 ± 0.91 | 0.21 ± 0.93 | −0.31 (−0.78; 0.17) |
| Statin (n = 25) | 0.74 ± 0.52 | 0.64 ± 0.49 | −0.10 ± 0.74 | |
| Triglycerides (g/L) | ||||
| Placebo (n = 26) | 1.55 ± 1.10 | 1.27 ± 0.69 | −0.28 ± 0.83 | 0.09 (−0.27; 0.46) |
| Statin (n = 25) | 1.16 ± 0.59 | 0.97 ± 0.43 | −0.18 ± 0.36 | |
| Glycemia (mmol/L) | ||||
| Placebo (n = 26) | 5.18 ± 0.51 | 5.03 ± 0.56 | −0.15 ± 0.57 | 0.06 (−0.34; 0.46) |
| Statin (n = 25) | 5.18 ± 0.76 | 5.01 ± 0.57 | −0.09 ± 0.83 | |
| Insulinemia (mUI/L) | ||||
| Placebo (n = 26) | 9.84 ± 8.02 | 8.20 ± 6.15 | −1.63 ± 5.12 | −2.27 (−8.96; 4.42) |
| Statin (n = 25) | 11.07 ± 16.38 | 7.16 ± 3.19 | −3.90 ± 15.56 | |
| HOMA | ||||
| Placebo (n = 26) | 2.39 ± 2.05 | 1.83 ± 1.47 | −0.56 ± 1.42 | −0.66 (−2.83; 1.51) |
| Statin (n = 25) | 2.83 ± 5.19 | 1.61 ± 0.77 | −1.22 ± 5.11 | |
| Hemoglobin A1c (%) | ||||
| Placebo (n = 26) | 5.60 ± 0.42 | 5.64 ± 0.40 | 0.04 ± 0.25 | 0.04 (−0.12; 0.19) |
| Statin (n = 25) | 5.64 ± 0.41 | 5.71 ± 0.43 | 0.08 ± 0.30 |
Data are mean ± SD. LDL, low-density lipoprotein; HDL, high-density lipoprotein; HOMA, homeostasis model assessment of insulin resistance.
$ P < 0.05 for value group, § P < 0.0001 value visit, £ P < 0.0001 value interaction, by repeated measure two-way ANOVA, followed by a Bonferroni post hoc test when necessary.